Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16052583 | 0.87 | SGK1 (0.67) | SGK1 | |
| SCHEMBL16065969 | 0.79 | SGK1 (1.00) | SGK1 | |
| SCHEMBL30251879 | 0.79 | SGK1 (1.00) | SGK1 | |
| SCHEMBL16065968 | 0.78 | SGK1 (1.00) | SGK1 | |
| SCHEMBL16053442 | 0.76 | SGK1 (0.74) | SGK1 | |
| SCHEMBL17457668 | 0.76 | SGK1 (0.78) | SGK1 | |
| SCHEMBL16065967 | 0.75 | SGK1 (1.00) | SGK1 | |
| SCHEMBL17472083 | 0.74 | SGK1 (0.57) | SGK1 | |
| SCHEMBL16053572 | 0.74 | SGK1 (0.54) | SGK1 | |
| SCHEMBL16053062 | 0.74 | SGK1 (0.83) | SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4147700-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | LQT Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | SGK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.